Introduction
============

Nerve injury-induced neuropathic pain due to diabetic neuropathy, viral infection, and chemotherapy is a major health problem worldwide ([@B56]; [@B10]; [@B6]; [@B19]). Similarly, common major surgeries frequently lead to the development of chronic post-operative pain (POP; [@B19]). Orthopedic injuries and subsequent surgery, such as tibial fracture and repair, produce sustained POP for many weeks that can greatly affect the quality of life in susceptible patients. Fracture associated POP (fPOP) is related to nerve injury, as reflected by a robust induction of the transcription factor ATF3 in sensory neurons, as well as neuroinflammation in the peripheral and central nervous system ([@B21]; [@B61]). Over the past three decades, great progress has been made in clarifying the mechanisms underlying the pathogenesis of pain after inflammation and nerve injury. It is generally accepted that pathological pain is caused by neural plasticity in primary sensory neurons (peripheral sensitization), spinal cord dorsal horn, and brain neurons (central sensitization; [@B12]; [@B55]; [@B16]). Dysregulation of glial cells (gliopathy) also contributes to the pathogenesis of pain in part by promoting neuroinflammation ([@B27]; [@B17], [@B16]; [@B47]).

Despite our progress in understanding the induction mechanisms producing the perception of pain ([@B18]), failure to resolve acute pain may in fact lead to the transition to chronic and maladaptive pain states ([@B18]; [@B52]). Serhan and his coworkers have demonstrated that the resolution of acute inflammation is an active process and requires biosynthesis of specialized pro-resolving mediators (SPMs). SPMs, such as resolvins, lipoxins, neuroprotectins, and maresins, are derived from omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and exhibit potent anti-inflammatory and pro-resolution actions in various animal models of inflammation ([@B37]; [@B28]). Many groups have demonstrated that peripheral, spinal, or systemic administration of lipoxins (LXA~4~), resolvins such as RvD1, D2, and E1 (RvD1, RvD2, and RvE1), NPD1, and MaR1 at very low doses (nanogram range), effectively reduced inflammatory pain ([@B44]; [@B3]; [@B59]; [@B22]; [@B32],[@B33]; [@B41]; [@B46]), POP after thoracotomy and muscle retraction ([@B14]; [@B49]), as well as neuropathic pain after nerve injury ([@B57],[@B58]) and spinal cord injury ([@B26]).

Although SPMs have been tested in several animal models of persistent pain, the following issues remain to be addressed: (1) the unique role of different SPMs in fPOP has not been investigated; (2) RvD3, RvD4, and RvD5 are identified new members of resolvin family and their complete stereochemical structures and total organic synthesis were recently achieved ([@B39]; [@B9]; [@B30], [@B31]; [@B54], [@B53]), but their involvement in pain is unexplored; (3) it is unclear whether SPMs can be produced and converted, under surgical manipulations (sham surgery vs. bone fracture) from their fish oil precursor DHA; and (4) it is also unclear if SPMs and their precursor (fish oil) exert differential effects in preventing or treating/reversing pathological pain. The present study was designed to address these questions by focusing on DHA and DHA-derived SPMs (RvD1, RvD3, RvD4, RvD5, NPD1, and MaR1) in a clinically relevant surgical pain model. Our results demonstrate unique analgesic effects of DHA and SPMs in preventing and reversing fPOP, revealing distinct production of SPMs after sham surgery and bone fracture.

Materials and Methods {#s1}
=====================

Animals and Surgery
-------------------

Adult CD1 mice (male, 25--35 g) were purchased from Charles River Laboratories. All animal procedures performed in this study were approved by the Animal Care Committee of Duke University and the ethics guidelines of International Association for the Study of Pain were followed ([@B63]). Tibial facture was performed under isoflurane anesthesia as we described previously ([@B61]; [@B25]). Muscles were disassociated following an incision on the left hind paw. A 0.38-mm stainless steel pin was inserted into the tibia intramedullary canal, followed by the osteotomy. The incision was sutured with 6-0 Prolene.

Drugs and Administration
------------------------

Docosahexaenoic acid, RvD1, RvD5, and MaR1 were purchased from Cayman Chemicals. RvD3 and RvD4 were validated with authentic standards (Serhan Lab). NPD1 was a kind gift from Resolvyx Pharmaceuticals, Inc. (Cambridge, MA, United States). For perioperative treatment, DHA (500 μg, 100 μl) or SPMs (500 ng, 100 μl) were dissolved in 2% ethanol as vehicle and administered intravenously through tail vein injection at 10 min and 24 h after surgery. For intrathecal (IT) injection, spinal cord puncture was made with a 30G needle between the L5 and L6 levels to deliver reagents (10 μl, 500 μg DHA or 500 ng SPMs, dissolved in 10% ethanol) into the cerebral spinal fluid ([@B15]). Intravenous or IT injections were given under brief isoflurane anesthesia.

ELISA Analysis
--------------

Mouse RvD1 ELISA kit was purchased from Cayman Chemicals (Catalog number 500380). The detection sensitivity of this ELISA kit is 15 pg/ml, where is sufficient to detect RvD1 levels in our samples. Serum, spinal cord, and brain tissues were collected from animals before and 5 days after the tibia surgery. Spinal cord and brain tissues were homogenized in a lysis buffer containing protease and phosphatase inhibitors ([@B62]). Tissue samples were centrifuged at 12,500 × *g* for 10 min and the supernatant was collected. Protein concentrations were determined by BCA Protein Assay (Pierce). For each reaction in a 96-well plate, 100 μg of proteins of brain and spinal cord samples and 25 μl of serum were used. ELISA was performed according to the manufacturer's protocol. The samples and the competition RvD1 tracer \[RvD1 linked to acetyl-cholinesterase (AChE)\] were incubated overnight at 4°C. The signal in ELISA plate was developed by Ellman's Reagent, a substrate of AChE. The optical densities of samples were measured using an ELISA plate reader (Bio-Rad) at a wavelength of 412 nm and RvD1 levels were calculated using the standard curves. The standard curve was included in each experiment. The RvD1 values of the samples were in the linear range of the standard curves.

Behavioral Analysis
-------------------

Animals were habituated to the testing environment daily for at least 2 days before starting baseline assessment. The room temperature and humidity remained stable throughout the experiments. For testing mechanical sensitivity, animals were put in boxes on an elevated metal mesh floor and allowed 30 min for habituation before examination. The plantar surface of each hind paw was stimulated with a series of von Frey hairs with logarithmically incrementing stiffness (0.02--2.56 g, Stoelting), presented perpendicularly to the plantar surface. Mechanical allodynia was assessed by the frequency response to a sub-threshold low force von Frey hair. Hind paws were stimulated with a 0.16 g von Frey hair for 10 times and the percentage withdrawal response was calculated as frequency ([@B25]). To assess cold allodynia, two acetone applications (20 μl each) were gently applied to the hind paw bottom using a pipette and the responses to acetone were scored as: 0, no response; 1, quick withdrawal, paw stamping, or flicking; 2, prolonged withdrawal or repeated flicking of the paw; and 3, repeated paw flicking and licking ([@B13]). The experimenter was blinded to the treatments.

Quantification and Statistics
-----------------------------

All data were expressed as mean ± SEM. Statistical analyses were completed with Prism GraphPad 6.0. Differences between groups were compared using two-way or one-way ANOVA followed by Bonferroni *post hoc* test. The criterion for statistical significance was *P* \< 0.05.

Results
=======

Sham Surgery Produces a Transient Post-operative Pain That Resolves in a Week
-----------------------------------------------------------------------------

We first examined mechanical and cold hypersensitivity in sham surgery mice subjected to skin and muscle incision but no pin insertion and bone fracture. Von Frey testing revealed a mild and transient (\<7 days) reduction in paw withdrawal threshold in the sham animals. This result suggests that sham surgery procures transient mechanical allodynia, and this acute pain resolves within a week (*P* \< 0.05, one-way ANOVA, **Figure [1A](#F1){ref-type="fig"}**). We also assessed mechanical allodynia measuring frequency responses to a subthreshold von Frey filament (0.16 g) and observed a transient increase (\<7 days) in paw withdrawal frequency (*P* \< 0.05 vs. baseline, one-way ANOVA, **Figure [1B](#F1){ref-type="fig"}**). The acetone test revealed that sham surgery also caused a slight increase in cold response scores for 5 days (*P* \> 0.05, one-way ANOVA, **Figure [1C](#F1){ref-type="fig"}**). Together, these results indicate that sham surgery produces transient mechanical and cold allodynia. Thus, this acute surgical pain model can serve as an animal model of pain resolution.

![Effects of sham surgery, bone fracture, and perioperative DHA treatment on the development of fPOP. Development of mechanical allodynia, assessed by paw withdrawal threshold **(A)** and paw withdrawal frequency to 0.16 g filament **(B)** in von Frey test, after sham surgery, tibial bone fracture, and perioperative treatment of DHA (0.5 mg, 100 μl, i.v.), given 10 min and 24 h after bone fracture surgery (indicated by blue arrows). **(C)** Development of cold allodynia, assessed by cold response scoring in the acetone test, after sham surgery, tibial bone fracture, and the perioperative DHA treatment after bone fracture surgery (indicated by blue arrows). \$*P* \< 0.05, one-way ANOVA in Sham group vs. baseline; ^∗^*P* \< 0.05 vs. Sham surgery; \#*P* \< 0.05, fracture vs. fracture + DHA; two-way ANOVA followed by Bonferroni test, *n* = 6--7 mice/group. Data are presented as mean ± SEM.](fphar-09-00412-g001){#F1}

Tibia Fracture Produces Persistent fPOP, Which Is Partially Prevented by Systemic Perioperative Treatment of DHA
----------------------------------------------------------------------------------------------------------------

Compared to sham surgery, tibial bone fracture induced persistent fPOP, as revealed by persistent mechanical allodynia (*P* \< 0.05), i.e., decrease in paw withdrawal threshold (**Figure [1A](#F1){ref-type="fig"}**) and increase in paw withdrawal frequency to a sub-threshold von Frey filament (0.16 g), which would not elicit pain under the normal conditions (**Figure [1B](#F1){ref-type="fig"}**). fPOP also manifested a persistent cold allodynia using the acetone test (**Figure [1C](#F1){ref-type="fig"}**, *P* \< 0.05). Next, we investigated whether perioperative administration of DHA, at 10 min and 24 h after the surgery, would protect from fPOP. Notably, intravenous injections of DHA (500 μg, 100 μl) significantly attenuated mechanical allodynia (*P* \< 0.05 vs. vehicle control) by decreasing paw withdrawal frequency (**Figure [1B](#F1){ref-type="fig"}**). Compared to vehicle control, cold allodynia was not significantly reduced (*P* \> 0.05) by DHA (**Figure [1C](#F1){ref-type="fig"}**). However, cold allodynia in the treatment group was also not significantly different from sham surgery, suggesting a possible inhibition of cold allodynia by the DHA pre-treatment (**Figure [1C](#F1){ref-type="fig"}**).

Sham Surgery but Not Orthopedic Surgery Increases RvD1 Levels in Serum and Spinal Cord
--------------------------------------------------------------------------------------

We examined RvD1 levels using a recently developed ELISA kit (Cayman Chemical). The assay reliably produced the expected RvD1 standard curve (**Figure [2A](#F2){ref-type="fig"}**). RvD1 levels were measured in serum, spinal cord, and brain tissue samples of naïve mice and mice after sham surgery and bone fracture. Samples were collected on day 5 after surgery, because DHA produced robust analgesic effects at this time point. Interestingly, compared to naïve animals and fracture surgery animals, sham surgery increased RvD1 levels in serum (63.58 pg/ml in naïve and 273.6 pg/ml in sham, *P* \< 0.05) but not in brain or spinal cord samples (**Figures [2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}**), indicating that serum RvD1 level may be correlated with resolution of acute pain in sham animals.

![Perioperative DHA treatment increases RvD1 levels in serum and spinal cord. **(A)** RvD1 standard curve produced by the Cayman Chemical ELISA assay, demonstrating reliable measurements within the specified concentration range. RvD1 levels in serum samples **(B)**, brain samples **(C)**, and spinal cord samples **(D)** of naïve mice and mice after sham surgery or bone fracture with vehicle and DHA treatment (the same as described in **Figure [1](#F1){ref-type="fig"}**). Samples were collected at post-operative day 5 (POD 5). Note that RvD1 levels are elevated after sham surgery and in serum and spinal cord samples after the DHA treatment. ^∗^*P* \< 0.05, one-way ANOVA; *n* = 3--10 mice per group. Data are presented as mean ± SEM.](fphar-09-00412-g002){#F2}

Perioperative DHA Treatment Increases RvD1 Levels in Serum and Spinal Cord
--------------------------------------------------------------------------

We then measured RvD1 levels in serum, spinal cord, and brain tissue samples of naïve, sham surgery, and bone fracture mice after vehicle and DHA pre-treatment. Samples were collected at day 5 after surgery as described above. Importantly, RvD1 levels were elevated in serum (271.4 vs. 74.96 pg/ml, *P* \< 0.05) and spinal cord samples (1063 vs. 324.4 pg/mg, *P* \< 0.05) after systemic DHA pre-treatment (**Figures [2B,D](#F2){ref-type="fig"}**). There was also a tendency for RvD1 levels to increase in the brain (**Figure [2C](#F2){ref-type="fig"}**). These data suggest that (1) sham surgery alone, but not bone fracture, can increase RvD1 production or/and its release and (2) DHA might be converted to SPMs such as RvD1 following pre-treatment in this fPOP model.

Perioperative Treatment of RvD1 and MaR1 Partially Prevents the Development of fPOP
-----------------------------------------------------------------------------------

RvD1 and MaR1 are DHA-derived SPMs ([@B37]). We investigated the potential anti-allodynic effects of RvD1 and MaR1 treatment (500 ng, i.v.) compared to DHA. Notably, RvD1 and MaR1 given at 10 min and 24 h after surgery significantly reduced mechanical and cold allodynia (*P* \< 0.05 vs. vehicle). Notably, MaR1 was more effective that RvD1 in reducing allodynia at some time points (**Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**). Thus, SPMs, and especially MaR1, can delay and partially prevent the development of fPOP, at a much lower dose than DHA.

![Perioperative treatment of RvD1 and MaR1 attenuates fPOP. Impact of perioperative treatment of RvD1 and MaR1 (500 ng, 100 μl, i.v.), given 10 min and 24 h after bone fracture surgery (indicated by blue arrows), on mechanical allodynia, assessed by paw withdrawal threshold **(A)** and paw withdrawal frequency **(B)** in the von Frey test, as well as on cold allodynia, assessed by cold response scoring in the acetone test **(C)**. ^∗^*P* \< 0.05 vs. vehicle (5% ethanol), two-way ANOVA followed by Bonferroni test, *n* = 5 mice/group. Data are presented as mean ± SEM.](fphar-09-00412-g003){#F3}

Spinal Post-operative Treatment of DHA Fails to Inhibit fPOP
------------------------------------------------------------

Spinal post-operative treatment of DHA (10--100 μg) via the IT route was shown to inhibit inflammatory pain following complete Freund's adjuvant and carrageenan injection, but not neuropathic pain (100 μg) after nerve ligation ([@B59], [@B58]; [@B24]). We assessed whether spinal post-treatment of DHA at a higher dose (500 μg, IT) would reduce established fPOP. IT injection of DHA, 2 weeks after surgery, produced no significant inhibition (*P* \> 0.05) of fracture-induced mechanical and cold allodynia, compared to vehicle injection, although there was a tendency for inhibition (**Figures [4A](#F4){ref-type="fig"}--[C](#F4){ref-type="fig"}**). It is noteworthy that vehicle injection (10% ethanol, IT) did not affect mechanical and cold allodynia (**Figures [4A](#F4){ref-type="fig"}--[C](#F4){ref-type="fig"}**).

![Distinct actions of post-treatment of DHAand DHA-derived SPMs on fPOP. Impact of post-surgical treatment with DHA (500 μg, i.t.) or DHA-derived SPMs RvD1, MaR1, NPD1, and RvD5 (500 ng, 10 μl, i.t.), given 2 weeks after bone fracture surgery (indicated by blue arrows) on mechanical allodynia, assessed by measurements of paw withdrawal threshold **(A)** and paw withdrawal frequency **(B)** in the von Frey test, as well as of cold allodynia, assessed by cold response scoring in the acetone test **(C)**. Note that post-treatment of DHA has no effects on fPOP. ^∗^*P* \< 0.05 vs. vehicle (10% ethanol), two-way ANOVA followed by Bonferroni test, *n* = 5--7 mice/group. Data are presented as mean ± SEM.](fphar-09-00412-g004){#F4}

Spinal Post-operative Treatment of DHA-Derived SPMs Differentially Regulates fPOP
---------------------------------------------------------------------------------

Next, we investigated the effects of DHA-derived SPMs, including RvD1, NPD1, and MaR1, since systemic and local applications of these SPMs (10--500 ng) have been shown to inhibit inflammatory and neuropathic pain([@B37], [@B38]; [@B18]; [@B32]). Spinal post-operative treatment with RvD1, NPD1, and MaR1 (500 ng, IT), given 2 weeks after the surgery, significantly reduced mechanical and cold allodynia (*P* \< 0.05 vs. vehicle). Interestingly, NPD1 and MaR1 were more effective than RvD1 in reducing mechanical and cold allodynia at some time points (**Figures [4A](#F4){ref-type="fig"}--[C](#F4){ref-type="fig"}**).

RvD3, RvD4, and RvD5 are newly identified members of resolvin D family and their complete stereochemistry was recently established ([@B7]; [@B2]; [@B54]; [@B31]). However, their effects on pain remained untested. IT injection of RvD5 (500 μg, IT), 2 weeks after surgery, significantly reduced mechanical and cold allodynia (*P* \< 0.05, **Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}**). By contrast, IT RvD3 and RvD4 (500 ng) did not alter mechanical and cold allodynia (*P* \> 0.05, **Figures [5A](#F5){ref-type="fig"}--[C](#F5){ref-type="fig"}**).

![Area under curve (AUC) comparison of distinct post-treatment effects of DHA and DHA-derived SPMs on fPOP. **(A--C)** AUC showing the effects of post-surgical IT treatment of DHA (500 μg, 10 μl) and NPD1, MaR1, RvD1, RvD3, RvD4, and RvD5 (500 ng, 10 μl), given 2 weeks after bone fracture surgery on mechanical and cold allodynia. AUC data were collected at 1--5 h after the drug injection. ^∗^*P* \< 0.05 vs. vehicle (10% ethanol), two-way ANOVA followed by Bonferroni test, *n* = 5--7 mice/group. Data are presented as mean ± SEM.](fphar-09-00412-g005){#F5}

Finally, to further compare the post-operative treatment effects of DHA and DHA-derived SPMs, we plotted all the treatment groups together using area under the curve (AUC) analysis. Because the anti-allodynic effects of SPMs disappeared after 5 h, we only collected AUC data from 1, 3, and 5 h data points after the SPM treatment. One-way ANOVA analysis revealed significant inhibition of mechanical allodynia (**Figures [5A,B](#F5){ref-type="fig"}**) and cold allodynia (**Figure [5C](#F5){ref-type="fig"}**) by RvD1, RvD5, NPD1, and MaR1 (*P* \< 0.05). RvD5 and MaR1 produced the strongest inhibition of allodynia, whereas DHA only displayed a trend toward inhibition, even at a dose 1000-fold higher than the effective concentrations of the SPMs (**Figures [5A](#F5){ref-type="fig"}--[C](#F5){ref-type="fig"}**). Taken together, these data demonstrated distinct inhibition of fPOP by post-operative treatment with different SPMs.

Discussion
==========

There has been a substantial amount of pre-clinical and clinical research on the effects omega-3s (omega-3 unsaturated fatty acids, found in seafood and fish oil) supplements on cardiovascular diseases. However, the findings are inconsistent, as summarized by the National Center for Complementary and Integrative Health, US National Institutes of Health website^[1](#fn01){ref-type="fn"}^. For most other conditions for which omega-3s have been studied, definitive conclusions cannot yet be reached. There is more evidence that omega-3s found in seafood and fish oil may help to relieve pain in rheumatoid arthritis ([@B1]). SPMs may provide beneficial effects on cognition and neuroinflammation in aging and Alzheimer's disease, yet to date clinical studies remain inconclusive ([@B51]). [@B35] demonstrated the effectiveness of omega-3 fatty acid supplementation as a therapy for headache. A follow-up study further showed that targeted alterations in the ratios of dietary omega-3 and omega-6 fatty acids also improved quality of life parameters and reduced psychological distress among patients with chronic headache ([@B34]). Importantly, this study measured plasma concentrations of SPMs \[such as RvD2 and the immediate precursors of resolvins and neuroprotectins; 17-hydroxy-docosahexaenoic (17-HDHA) and 18-hydroxy-eicosapentaenoic acid (18-HEPE)\] and confirmed that SPMs are converted from dietary omega-3 supplements ([@B35]; [@B48]), suggesting that analgesic effects of fish oil and omega-3-enriched diets may be correlated with the increased production of SPMs. Compared to EPA, DHA is highly enriched in membrane phospholipids of the nervous system and, therefore, plays a more important role in neuroprotection in neurological and neuropsychiatric diseases ([@B60]; [@B23]; [@B42]). In three large US cohorts, higher circulating levels of DHA are inversely associated with incident atherothrombotic stroke ([@B36]). Thus, we focused this study on DHA and DHA-derived SPMs. We found that systemic pre-treatment with DHA during the perioperative period (10 min and 24 h after the surgery, 500 μg per mouse, i.v.) alleviated post-surgical pain, especially mechanical hypersensitivity after tibia fracture (**Figure [1](#F1){ref-type="fig"}**).

Our study also demonstrated that perioperative DHA treatment resulted in increased biosynthesis of RvD1 in serum and in spinal cord (**Figure [2](#F2){ref-type="fig"}**). Notably, the elevation of RvD1 in the spinal cord was significantly higher than what we measured in the brain on POD5. Especially after the systemic DHA treatment, we found significant increases in RvD1 levels in serum and spinal cord samples but not in brain samples (**Figures [2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}**). This difference in DHA conversion to RvD1 may result from different activities of the synthesis enzymes such as lipoxygenase (5/15-LOX) in serum and spinal cord vs. brain, since these enzymes are involved in the biosynthesis of RvD1 ([@B18]). Future studies are needed to examine different regulations of 5/15-LOX expression in blood, spinal cord, and brain tissues after tibial fracture. It is likely that bone fracture causes more upregulations of 5/15-LOX in spinal cord and blood compared to brain. We previously described acute changes (POD1-3) in cognition and glia activation in the brain after orthopedic surgery ([@B45], [@B46]), suggesting that the resolution of inflammation differs between the brain and the spinal cord. The mechanisms underlying supraspinal effects and communication from the spinal cord to the brain warrant further investigation. In our studies, we also found that perioperative treatment with RvD1 at a much lower dose (500 ng per mouse, i.v.) reduced the development of fPOP, although MaR1 appears to be more effective than RvD1 (**Figure [3](#F3){ref-type="fig"}**). Further industrial and academic efforts are warranted to optimize ELISA kits for various SPMs without requiring lipidomic platforms. Notably, the effective doses of SPMs in protecting from fPOP in mice are 1000 times lower than for their DHA precursor, as we have previously shown in inflammatory pain conditions ([@B59]). It is conceivable that the therapeutic effect of perioperative DHA treatment is associated with its conversion to SPMs and these mechanisms warrant further consideration.

Another interesting finding of this study is that sham surgery caused a significant increase in serum RvD1 levels on POD5 compared to naïve control. Importantly, this increase was associated with a transient development of mechanical and cold allodynia that resolved on day 7 (**Figure [1](#F1){ref-type="fig"}**), suggesting that early SPM production may be responsible for the resolution of acute pain following sham surgery. This is also in agreement with our previous studies as SPMs are synthesized during the resolution phase of acute inflammation ([@B37]). Thus, we also propose that a failure in SPMs biosynthesis can drive chronic inflammation ([@B37]; [@B18]). Indeed, RvD1 levels after bone fracture were lower than the levels measured after sham surgery and in naïve animals (**Figure [2](#F2){ref-type="fig"}**). It is suggested that dysfunction of the biosynthetic pathway of SPM production may result in a transition from acute to chronic POP. While paw incision and muscle retraction produce acute POP ([@B5]; [@B14]), fPOP represents a unique orthopedic surgical model that produces long-lasting POP for many weeks ([@B50]). In our previous work, we did not find significant changes in mechanical allodynia with opioid analgesia and using a different mouse strain (C57BL/6), suggesting that other factors may influence this response ([@B61]). However, as confirmed in this study, the development of cold allodynia is robust and may indicate unique signaling pathways triggered by orthopedic surgery that are consistent with clinical evaluations in post-fracture patients ([@B40]). It remains to be tested whether SPM or DHA pre-treatment can delay or prevent fPOP. Unlike other POP models, fPOP may manifest as both inflammatory pain and neuropathic pain. In fact, the tibial fracture model used here is regarded as a model for complex regional pain syndrome ([@B50]). It also produces marked nerve injury, as revealed by increased ATF3 expression in DRG neurons ([@B61]), which is reminiscent of ATF3 induction upon thoracotomy that produces long-lasting neuropathic pain ([@B8]).

It is noteworthy that post-operative treatment with DHA (500 μg, i.t.), 2 weeks after orthopedic surgery, failed to reduce established fPOP (**Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}**). This is in agreement with our previous report that IT DHA (600 μg, given 2 weeks after surgery) did not alter neuropathic pain after nerve ligation ([@B58]). However, IT post-treatment of NPD1 was as effective as gabapentin in attenuating nerve injury-induced late-phase mechanical allodynia, despite a striking dose difference (500 ng NPD1 vs. 100 μg gabapentin; [@B58]). Despite the effectiveness of the post-operative treatment, we also have to point out that SPMs are more effective in preventing the development of chronic POP and neuropathic pain ([@B14]; [@B58]; [@B49]).

Given the rapid expansion of SPMs, it is important to understand distinct roles of SPMs in the resolution of inflammation and pain. We employed AUC analysis to compare the analgesic efficacy of different DHA-derived SPMs following IT post-treatment 2 weeks after orthopedic surgery. It is of interest that among these SPMs MaR1, NPD1, and RvD5 are more effective than RvD1, RvD3, and RvD4 (**Figure [5](#F5){ref-type="fig"}**). Mechanistically, SPMs resolve acute inflammation by modulating the function of immune cells, such as phagocytosis of macrophages ([@B37]). In this study, we evaluated different families of SPMs derived both from the DHA and EPA pathways. These differentially impact G protein-coupled receptor (GPCR) superfamily signaling, which may provide insights into potency and efficacy in different models. Increasing evidence suggests that neuroinflammation, as characterized by activation of glial cells and generation of pro-inflammatory cytokines in the peripheral and central nervous system, plays a critical role in the development and maintenance of chronic pain ([@B16]). SPMs such as NPD1 and RvE1 control neuroinflammation by inhibiting glial activation and release of TNF and IL-1β in glial cells ([@B57],[@B58]). Recent work by [@B4] showed that RvD1 also reduces glia activation, both in microglia and astrocytes, and prevented neuronal cell death after remote brain damage. Prophylaxis with aspirin-triggered RvD1 is also effective in protecting the brain from cognitive deficits after surgery by reducing astrocyte activation and neuronal plasticity ([@B46]). Importantly, aspirin jumpstarts resolution by generating AT-RvD1 with the 17R configuration of its carbon 17 position, which provides longer lasting *in vivo* effects ([@B43]). Mimetics of endogenous SPMs, such as targeted nanoparticles, also provide an attractive therapeutic strategy to extend the therapeutic effects and improve delivery of bioactive compounds ([@B29]; [@B11]; [@B20]). SPMs also regulate the function of nociceptive neurons in the PNS and of pain circuits within the CNS. For example, RvE1, RvD1, RvD2, and NPD1 inhibit spinal cord synaptic plasticity after inflammation and nerve injury and the function of TRPA1 and TRPV1 ion channels ([@B59], [@B58]; [@B32],[@B33]).

Conclusion
==========

Docosahexaenoic acid and SPMs have distinct potent analgesic actions in preventing and reversing fPOP and chronic pain; for the pretreatment, 1000 times higher amounts of DHA were required than the SPM, which are active in the nanogram range. It is significant and possibly cost saving to implement pro-resolution-derived therapies to prevent the development of chronic neuropathic pain after orthopedic surgery and other conditions, such as chemotherapy, that share similar endpoints. We expect strategies that target endogenous resolution programs to be beneficial in treating several complications within perioperative care and patient's recovery.
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MaR1

:   maresin 1: 7*R*,14*S*-dihydroxy-4*Z*,8*E*,10*E*,12*Z*,16*Z*,19*Z*-docosahexaenoic acid

NPD1

:   neuroprotectin D1: 10*R*,17*S*-dihydroxy-4*Z*,7*Z*,11*E*,13*E*,15*Z*,19*Z*-docosahexaenoic acid

RvD1

:   Resolvin D1: 7*S*,8*R*,17 *S*-trihydroxydocosa-4*Z*,9*E*,11*E*, 13*Z*,15*E*,19*Z*-hexaenoic acid

RvD2

:   Resolvin D2: 7*S*,16*R*,17*S*-trihydroxydocosa-4*Z*,8*E*,10*Z*,12*E*,14*E*,19*Z*-hexaenoic acid

RvD3

:   Resolvin D3: 4*S*,11*R*,17*S*-trihydroxydocosa-5*Z*,7*E*,9*E*,13*Z*,15*E*,19*Z*-hexaenoic acid

RvD4

:   Resolvin D4: 4*S*,5*R*,17*S*-trihydroxydocosa-6*E*,8*E*,10*Z*,13*Z*,15*E*,19*Z*-hexaenoic acid

RvD5

:   Resolvin D5: 7*S*,17*S*-dihydroxy-4*Z*,8*E*,10*Z*,13*Z*,15*E*,19*Z*-docosahexaenoic acid
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